OptiNose Inc
NASDAQ:OPTN
OptiNose Inc
NASDAQ:OPTN
Price:
9.6
USD
-1.13%
Market Closed
Market Cap:
$97.2m
Relative Value
The Relative Value of one
OPTN
stock under the Base Case scenario is
20.6
USD.
Compared to the current market price of 9.6 USD,
OptiNose Inc
is
Undervalued by 53%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OPTN
Relative Value
Base Case
20.6
USD
Undervaluation 53%
Multiples Across Competitors
OPTN Competitors Multiples
OptiNose Inc Competitors
OptiNose Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
OptiNose Inc
NASDAQ:OPTN
|
96.6m USD | 1.2 | -4.5 | -8.6 | -8.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
946.1B USD | 14.5 | 45.8 | 30.9 | 33 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.8B USD | 6.2 | 21.9 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
263.4B CHF | 4.3 | 20.4 | 12 | 13.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.3B GBP | 5.1 | 29.5 | 16.3 | 23 | |
| CH |
|
Novartis AG
SIX:NOVN
|
232.9B CHF | 5.3 | 21.4 | 13.3 | 17 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 4.5 | 15.9 | 9.9 | 12 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.4B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121B USD | 2.5 | 17.2 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
